ArticleArchives of dermatological research2025
Therapy resistant hypertrophic lichen planus and its response to oral tofacitinib with a priori tissue cytokine expression: a real-world hospital-based study.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence.Mediators of inflammation · 2026Pooled it
- Authors' Response to Comment on published article "A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale".Indian dermatology online journal · 2026Article
- Use of JAK Inhibitors in Lichen Planus: An Update.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough there are several reports on use of tofacitinib in lichen planus (LP), its usage in hypertrophic LP is sparse with no data on tissue cytokine expression.
methodsWe retrospectively analyzed the records of recalcitrant hypertrophic LP patients treated with tofacitinib monotherapy. Demographic and clinical details were noted. We assessed Th1, Th2, Th17 cytokines in lesional and non-lesional tissue samples using real time PCR. Dose, duration and response to tofacitinib in terms of resolution of lesions and pruritus was noted. Side effects and time after which relapses were seen post treatment were recorded.
resultsFifteen hypertrophic LP patients were analysed with a mean age of 34.06years (18-59years, 8 females and 7 males). Previous failed systemic treatments included corticosteroids(n = 1), retinoids(n = 5), cyclosporine(n = 8), methotrexate(n = 8) and thalidomide(n = 3). Tissue cytokine analysis was performed in 3/15 patients which showed upregulation of Th1 and Th17 cytokines [Interferon-γ, Interleukin (IL)-17 and IL-21]. Mean dose of tofacitinib was 11.6 mg (10-15 mg) and was given for a mean duration of 8.8weeks (8-16weeks). Pruritus resolved in a mean duration of 8.6days and mean time to achieve resolution of lesions was 4.69weeks. Two patients failed to show improvement and drug was stopped after 8 weeks. Side effects were noted in 6 patients [dyslipidemia(n = 2), upper respiratory infection(n = 2), fever(n = 1) and folliculitis(n = 1)]. Relapse was noted in 5/13 patients [38.46%, mean time duration: 7.2weeks (4-12weeks)].
conclusionA predominant Th1/Th17 cytokine profile was noted in the subset analysed and was extrapolated to the use of oral tofacitinib in hypertrophic LP patients.
Indexed as
Identifiers
40095121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.